Difference between revisions of "Breast cancer"
Jump to navigation
Jump to search
(Created page with "==Adjuvant Therapy== ==Metastatic Disease== ===Single agents=== ====Halaven==== *Eribulin (Halaven) 1.4 mg/m2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cy...") |
|||
| Line 2: | Line 2: | ||
==Metastatic Disease== | ==Metastatic Disease== | ||
===Single agents=== | ===Single agents=== | ||
| − | ====Halaven==== | + | ====Eribulin (Halaven)==== |
| − | *[[Eribulin (Halaven)]] 1.4 mg/m2 | + | *[[Eribulin (Halaven)]] 1.4 mg/m2 IV over 2 to 5 minutes on days 1 and 8 |
| + | |||
| + | '''21-day cycles''' | ||
=====References===== | =====References===== | ||
| − | # Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. | + | # Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960070-6/fulltext link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/21376385 PubMed] |
| − | |||
Revision as of 06:52, 18 February 2012
Adjuvant Therapy
Metastatic Disease
Single agents
Eribulin (Halaven)
- Eribulin (Halaven) 1.4 mg/m2 IV over 2 to 5 minutes on days 1 and 8
21-day cycles
References
- Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. link to original article (contains protocol) PubMed